©The Author(s) 2017.
World J Gastroenterol. May 28, 2017; 23(20): 3589-3606
Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3589
Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3589
Table 5 Comparison of clinical manifestations of hepatitis A virus between human immunodeficiency virus-positive patients or human immunodeficiency virus-negative patients with acute hepatitis A
| HIV-positive patients | HIV-negative patients | |
| Natural course of acute HAV infection | ||
| Incubation period (wk) | NA | 2.5-5[91] |
| Duration of stool shedding (d) | NA | 25 (HAV antigen)[105] |
| 81 (HAV RNA)[106] | ||
| Duration of viremia (d) | 53 (10-89)[25] | 22-95[25,106-108] |
| Laboratory findings | ||
| Peak T-bilirubin (mg/dL) | 5.1-5.9[25] | 5.7-8.7[25,92,93,95,98,99] |
| Peak AST (IU/L) | 929-1339[25,57] | 1231-2271[25,92,93,99] |
| Peak ALT (IU/L) | 1995-2368[25,57] | 1079-3442[25,92,93,99,100] |
| Duration of elevated AST/ALT (d) | 63 ± 38[109] | 51[92] |
| Peak ALP (IU/L) | 807[25,57] | 228-396[25,92] |
- Citation: Lin KY, Chen GJ, Lee YL, Huang YC, Cheng A, Sun HY, Chang SY, Liu CE, Hung CC. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review. World J Gastroenterol 2017; 23(20): 3589-3606
- URL: https://www.wjgnet.com/1007-9327/full/v23/i20/3589.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i20.3589